MINE regimen
|
WikiDoc Resources for MINE regimen |
|
Articles |
|---|
|
Most recent articles on MINE regimen Most cited articles on MINE regimen |
|
Media |
|
Powerpoint slides on MINE regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on MINE regimen at Clinical Trials.gov Clinical Trials on MINE regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on MINE regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on MINE regimen Discussion groups on MINE regimen Patient Handouts on MINE regimen Directions to Hospitals Treating MINE regimen Risk calculators and risk factors for MINE regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for MINE regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Mesna-Ifosfamide-Novantrone-Etoposide Regimen; MINE Regimen
Overview
MINE regimen refers to a regimen consisting of mesna, ifosfamide, mitoxantrone and etoposide used to treat relapsed or refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma.[1][2]
Regimen
MMesna
IIfosfamide
NMitoxantrone (Novantrone)
EEtoposide
Indications
Hodgkin's lymphoma and non-Hodgkin's lymphoma[1][3]
References
- ↑ 1.0 1.1 Fan Y, Huang ZY, Luo LH, Yu HF (2005). "[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]". Ai Zheng. 24 (12): 1503–6. PMID 16351801.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".